Antidiuretic Drugs Market Size, Share, and Industry Analysis By Drug (Vasopressin, Desmopressin, Oxytocin, and Others), By Route of Administration (Oral and Parenteral), By Indication (Hemophilia, Diabetes Insipidus, Nocturnal Polyuria, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast till 2032

Antidiuretics are drugs that help control fluid balance in the human body by reducing urination and opposing diuresis. They are often used to treat conditions such as diabetes insipidus. Diabetes insipidus is a disease in which the secretion of or response to the pituitary hormone vasopressin is impaired. This results in the production of very large quantities of dilute urine, often with dehydration and insatiable thirst. Moreover, they are used in the treatment of hemophilia and nocturia.

Antidiuretics reduce urine volume by increasing the reabsorption of water from the kidneys back into the circulation. The major endogenous antidiuretics are antidiuretic hormones such as vasopressin and oxytocin, which are used exogenously as medications in individuals whose bodies need additional help with fluid balance through suppression of diuresis. Antidiuretics work by exerting an antidiuretic action, which conserves body water by reducing the excretion of water in urine, thereby decreasing the volume of urine and increasing the reabsorption of water from the kidneys.

The increasing prevalence of diseases such as diabetes insipidus and hemophilia significantly boosts the adoption of antidiuretics in the treatment of such diseases, thereby contributing to the growth of the antidiuretic drugs market.

• For instance, according to Lancet Diabetes & Endocrinology, diabetes insipidus is a rare neuroendocrine condition with a prevalence of 1 in 25,000 individuals globally. This is caused by the deficiency of arginine vasopressin, which drives the demand for antidiuretics for the treatment and boosts the market growth.

The approval of antidiuretic products significantly boosts the market growth. These approvals are crucial as they allow for the introduction of new drugs into the market, catering to the rising demand for treatments related to conditions such as diabetes insipidus, hypertension, and hemophilia. Moreover, the increasing number of approvals for generic versions of antidiuretic drugs also supports the market expansion.

• For instance, in July 2022, Amphastar Pharmaceuticals, Inc. announced that it had received the Abbreviated New Drug Application (ANDA) approval from the U.S. FDA for vasopressin injection. This approval of antidiuretic drugs leads to the increased revenue growth rates of key players, driving the expansion of the global antidiuretic drugs market.

The COVID-19 pandemic had a significant impact on the sales of antidiuretic drugs. The pandemic led to an increased focus on an improved supply of antidiuretic drugs to meet the demand in critical care, including for administration in some of the most acute cases of COVID-19. For instance, in November 2021, Endo International plc's Par Sterile Products division provided Vasostrict, vasopressin injection, USP, in a vial to healthcare providers through the Premier ProRx program. This partnership ensured the consistent supply of this essential medication for critical care, including for the severe cases of COVID-19.

Key Insights

The report covers the following key insights:

• Incidence of Key Diseases, By Key Countries/Region, 2023


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Market     

Segmentation

Analysis by Drug

Based on drug, the vasopressin segment is expected to hold a significant share of the global antidiuretic drugs market during the forecast period. The segment growth is attributed to the high significance of vasopressin, such as increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. In addition, the increased focus of prominent market players in launching both new and generic versions of vasopressin drugs increases the availability of the drug in the market.

• For instance, in June 2023, Fresenius Kabi AG launched the generic version of Vasostrict, a vasopressin injection, to treat adults with vasodilatory shock in the U.S.

The high availability of the drug is anticipated to boost the segment growth during the projection period.

Regional Analysis

North America is anticipated to account for a significant growth of the antidiuretic drugs market during the forecast period. The growth is mainly attributed to the presence of prominent market players in the region, ensuring the supply and demand for antidiuretic drugs. The focus on research and development for antidiuretic drugs in the region leads to the introduction of novel forms of drugs in the region, thereby contributing to the market growth. Furthermore, the high incidence of hemophilia in the region is expected to boost the regional market growth.

• For instance, according to the Centers for Disease Control and Prevention,  hemophilia A affects around 1 in 5,000 of male births in the U.S. (July 2023)

The high incidence of hemophilia in the region considerably spurs the adoption of antidiuretic drugs, which is expected to surge the regional market growth.

Asia Pacific is projected to witness substantial growth over the forthcoming years. The growth of the region is attributed to the rising prevalence of nocturnal polyuria among the elderly population. This condition may result from decreased nocturnal secretion of antidiuretic hormone (ADH) in aged individuals. Antidiuretic drugs are the treatment of choice for this condition, which is anticipated to fuel the regional market growth over the coming years.

• For instance, in October 2023, according to Springer Nature Limited, the frequency of nocturnal polyuria (NP) varies with age among individuals experiencing nocturia. Analysis of Japanese patients by age groups revealed that the prevalence of nocturnal polyuria (NP) was 38.1% in those under 50 years, 55.3% in individuals aged 50-59, 56.7% among those aged 60-69, 66.5% in the 70-79 age group, and 79.3% in those aged 80 or older. The data suggests an upward trend in the prevalence of nocturnal polyuria (NP) with increasing age.

Key Players Covered

The report includes the profiles of key players such as Par Pharmaceutical, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, Avadel, Ferring B.V., Sanofi, Taj Pharmaceuticals Limited, CELON LABS, and Biocon.

Key Industry Developments

• In April 2024, Adalvo, in collaboration with strategic partners, announced the launch of desmopressin in multiple countries across Europe. This product was developed based on the reference brand Minirin Melt from Ferring B.V.


• In February 2024, Adalvo announced the launch of desmopressin sublingual tablets in France. This launch strengthened the company's pharmaceutical portfolio.

In February 2022, Dr. Reddy’s Laboratories Ltd. launched the generic version of Vasostrict (Vasopressin) in the U.S. market. This injection was supplied in a carton of 25 single-dose vials, each containing 1 mL vasopressin at 20 units/mL.